New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:53 EDTCBMGCellular Biomedicine releases positive ReJoin Phase I/IIa six-month data
Cellular Biomedicine released the six-month follow-up data analysis of its Phase I/IIa clinical trial for its Rejoin human adipose-derived mesenchymal precursor cell, or haMPC, therapy for Knee Osteoarthritis, or KOA. The trial, conducted by Shanghai Renji Hospital, tested the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. The primary endpoints for this trial were safety and knee-related pain, stiffness and function measured using the Western Ontario and McMaster Universities osteoarthritis index questionnaire. The secondary endpoints were cartilage repair at six months, defined through the volume of the repair tissue measured with quantitative magnetic resonance imaging as well as NRS-11, SF-36 and KSCRS scores.
News For CBMG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2015
12:00 EDTCBMGCellular Biomedicine mentioned cautiously by Pump Stopper blog
Reference Link
April 6, 2015
09:55 EDTCBMGCellular Biomedicine shares worth $5, Citron Research says
Shares of Cellular Biomedicine are worth $5 and should be shorted if a borrow is available, short-selling blog Citron Research says via Twitter. The stock is down $1.16 to $35.00 in early trading.
09:07 EDTCBMGCellular Biomedicine Shanghai facility passes fourth CFDA inspection
Cellular Biomedicine announced that its GMP laboratory and production facility in Shanghai has successfully passed a fourth consecutive China Food and Drug Administration, or CFDA, inspection.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use